Table 2.

Association between ATP III clinical identification of the MetS and metachronous adenomas

Any metachronous neoplasia (men n = 800 and women n = 305)
Nonadvanced neoplasia (men n = 563 and women n = 207)
Advanced neoplasia (men n = 236 and women n = 97)
Single metachronous neoplasia (men n = 382 and women n = 163)
Multiple metachronous neoplasia (men n = 418 and women n = 142)
%OR* (95% CI)%OR (95% CI)%OR (95% CI)%OR (95% CI)%OR (95% CI)
Men (n = 1,609)
    Waist circumference
        Low46.71.0032.91.0013.81.0023.21.0023.51.00
        High54.21.41 (1.15-1.72)38.11.41 (1.13-1.76)16.11.41 (1.05-1.90)24.51.25 (0.97-1.60)29.61.58 (1.23-2.02)
    Triglycerides (mg/dL)
        <15050.61.0035.01.0015.61.0024.11.0026.51.00
        ≥15048.50.94 (0.77-1.15)35.00.97 (0.78-1.20)13.40.87 (0.64-1.17)23.20.93 (0.73-1.19)25.30.95 (0.75-1.21)
    HDL
        High§50.71.0035.41.0015.21.0024.11.0026.61.00
        Low47.50.92 (0.74-1.14)34.00.94 (0.74-1.19)13.40.87 (0.63-1.21)22.90.91 (0.69-1.19)24.60.93 (0.71-1.21)
    Blood pressure (mm Hg)
        <130/<8549.61.0033.91.0015.71.0024.51.0025.11.00
        ≥130/≥8549.80.95 (0.77-1.16)35.81.01 (0.81-1.27)13.90.79 (0.59-1.07)23.20.92 (0.72-1.18)26.60.98 (0.76-1.25)
    Fasting glucose (mg/dL)
        <10049.61.0034.71.0014.91.0025.11.0024.51.00
        ≥10049.81.01 (0.82-1.23)35.21.03 (0.82-1.28)14.50.96 (0.71-1.29)22.80.91 (0.71-1.16)27.01.12 (0.87-1.43)
    MetS
        0-2 criteria50.91.0035.01.0015.21.0024.61.0025.61.00
        3-5 criteria49.10.99 (0.81-1.21)35.01.01 (0.81-1.26)14.00.93 (0.69-1.25)22.60.91 (0.71-1.17)26.51.07 (0.84-1.37)
Women (n = 783)
    Waist circumference
        Low36.01.0022.51.0013.51.0020.51.0015.51.00
        High44.11.41 (1.05-1.90)33.31.72 (1.23-2.41)10.50.89 (0.55-1.42)21.31.20 (0.83-1.74)22.71.72 (1.17-2.53)
    Triglycerides (mg/dL)
        <15037.31.0023.91.0013.31.0020.81.0016.51.00
        ≥15041.21.14 (0.85-1.53)29.81.28 (0.92-1.78)11.20.88 (0.56-1.38)20.91.05 (0.73-1.51)20.31.27 (0.87-1.86)
    HDL
        High§38.11.0024.91.0013.11.0020.81.0017.41.00
        Low41.11.13 (0.82-1.55)30.41.28 (0.89-1.82)10.70.86 (0.52-1.42)21.01.06 (0.71-1.57)20.11.21 (0.80-1.83)
    Blood pressure (mm Hg)
        <130/<8536.11.0023.71.0012.41.0020.91.0015.21.00
        ≥130/≥8541.41.13 (0.83-1.52)28.91.16 (0.82-1.63)12.41.04 (0.66-1.63)20.71.02 (0.71-1.48)20.71.27 (0.86-1.89)
    Fasting glucose (mg/dL)
        <10035.01.0023.41.0011.51.0018.91.0016.11.00
        ≥10045.01.46 (1.09-1.96)31.21.51 (1.08-2.11)13.81.39 (0.89-2.17)23.81.49 (1.04-2.14)21.21.44 (0.98-2.11)
    MetS
        0-2 criteria36.01.0023.31.0012.71.0020.01.0016.01.00
        3-5 criteria44.41.37 (1.01-1.85)32.31.52 (1.08-2.13)12.01.06 (0.67-1.69)22.41.27 (0.88-1.84)22.01.50 (1.02-2.21)
  • * OR from logistic regression adjusted for age and study.

  • OR from multinomial logistic regression adjusted for age and study.

  • Waist circumference classification for men: low ≤40 inches, high >40 inches; women: low ≤35 inches, high >35 inches.

  • § HDL cholesterol classification for men: high HDL ≥40 mg/dL, low HDL <40 mg/dL; women: high HDL ≥50 mg/dL, low HDL <50 mg/dL.

  • ATP III clinical identification of the MetS.